1[1]Kanamaru T, Takagi T, Takakura Y, et al. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes[J].J Drug Target,1998,5(4):235-237.
2[2]Yuen A, Advani R, Fisher G,et al.A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer[J]. Am Soc Clin Oncol, 2000,19(6): 459-461.
3[3]Webb A, Cunningham D, Cotter F,et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma[J].Lancet, 1997,349(9059):1137-1141.
4[4]Jansen B, Wacheck V, Heere-Ress E,et al.Chemosensitisation of malignant melanoma by BCL2 antisense therapy[J]. Lancet, 2000,356(9243):1728-1733.
5[5]Chi KN, Gleave ME, Klasa R,et al.A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer[J]. Clin Cancer Res,2001, 7(12):3920-3927.
6[6]C.M.Rudin, G.A.Otterson, A. M. Mauer, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer[J]. Annals of Oncology, 2002,13(4):539-545.
7[7]Banerjee D. Genasense (Genta Inc).Curr Opin Investig Drugs[J]. 2001, 2(4):574-580.
8[8]Fennell DA, Corbo MV, Dean NM,et al.In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model[J].Br J Haematol, 2001,112(3):706-713.
9[9]Monia BP. First and second-generation antisense inhibits targers to human c-raf kinase:in vitro and in vivo studies[J]. Anticancer Drugs Des,1997,12(5):327-339.
10[10]O'Dwyer PJ, Stevenson JP, Gallagher M, et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)[J]. Clin Cancer Res, 1999, 5(12): 3977-3982.
